1. Bayani
A sakamakon zurfafa ci gaban kayayyakin more rayuwa na likitanci, rarraba albarkatun kiwon lafiya masu inganci, da kuma amfani da tiyata mai ƙarancin tasiri, endoscope - a matsayin babban kayan aiki don gano cututtuka da magani na asibiti - yana shaida canjin kasuwa. Buƙatar tana canzawa daga "lura da hoto" na gargajiya zuwa "hoton hoto mai inganci" da "taimakon fasaha."
An gabatar a ƙasa wani cikakken bincike ne game da kasuwar endoscope a China na 2025.
A cewar bayanai, an bayar da sanarwar bayar da kyautar ga jama'a guda 14,281 ga na'urorin endoscopes a kasar Sin a shekarar 2025. Adadin sayayya ya kai raka'a/set/rukuni 51,121, tare da jimillar darajar tallace-tallace ta RMB biliyan 40.822. Waɗannan ayyukan sun shafi kamfanonin sayayya 3,697 da kuma masu tayin da suka yi nasara 3,968. Kason kasuwa na manyan kamfanoni kamar haka: Olympus (33.28%), Karl Storz (16.69%), Fujifilm (14.98%), Sonoscape (10.02%), da Mindray (8.88%). Abin lura shi ne, manyan samfuran guda uku sun kai kashi 64.95% na kasuwar.
Hoto na 1: Kasuwar Manyan Alamun Endoscope a China ta hanyar Tallace-tallace, 2025
Hoto na 2: Yanayin Kasuwa na Manyan Alamomi 5 na Endoscope a China (2022-2025) ta hanyar Adadin Talla
2. Bayani kan Kasuwa ta Nau'in Endoscope
Arthroscope
Adadin siyan kayan aiki masu alaƙa ya kai raka'a/seti/rukuni 2,399, tare da jimlar darajar tallace-tallace ta RMB biliyan 1.752. Kasuwar hannun jari ta hanyar kudaden shiga ga manyan samfuran kamar haka: Smith & Nephew (28.28%), Richard Wolf (21.23%), CONMED (11.94%), Stryker (11.91%), da Shenyang Shenda (8.72%). Manyan samfuran uku sun ƙunshi kashi 61.44% na kasuwar.
Hoto na 3: Yanayin Kasuwa na Manyan Alamun Arthroscope guda 5 a China (2022-2025) ta hanyar Adadin Talla
Gastroscope
Adadin siyan kayan aiki masu alaƙa ya kai raka'a/saiti/rukuni 10,052, tare da jimlar darajar tallace-tallace ta RMB biliyan 10.392. Kasuwar da aka samu ta hanyar kudaden shiga ga manyan samfuran an rarraba ta kamar haka: Olympus (43.85%), Fujifilm (27.12%), Sonoscape (13.17%), Aohua (10.34%), da Pentax (4.18%). Manyan samfuran uku gaba ɗaya sun ƙunshi kashi 84.14% na kasuwar.
Hoto na 4: Yanayin Kasuwa na Manyan Kayayyakin Gastroscope guda 5 a China (2022-2025) ta hanyar Adadin Talla
Bronchoscope
Adadin siyan kayan aiki masu alaƙa ya kai raka'a/saiti/rukuni 4,696, tare da jimlar darajar tallace-tallace ta RMB biliyan 2.717. Kasuwar da manyan kamfanoni ke samu ta hanyar samun kuɗi ita ce kamar haka: Seesheen (25.00%), Olympus (22.13%), Zhejiang UE MEDICAL (12.60%), Insighters (10.04%), da Fujifilm (8.83%). Manyan samfuran uku sun ƙunshi kashi 59.73% na kasuwar.
Hoto na 5: Yanayin Kasuwa na Manyan Kayayyakin Bronchoscope guda 5 a China (2022-2025) ta hanyar Adadin Talla
Laparoscope
Adadin siyan kayan aiki masu alaƙa ya kai raka'a/saiti/rukuni 11,750, tare da jimlar darajar tallace-tallace ta RMB biliyan 13.125. Kason kasuwa ta hanyar kudaden shiga ga manyan samfuran an rarraba shi kamar haka: Karl Storz (33.93%), Mindray (22.51%), Kangji Medical (12.72%), Olympus (10.99%), da OptoMedic (8.68%). Manyan samfuran uku sun ƙunshi kashi 69.16% na kasuwar.
Hoto na 6: Yanayin Kasuwa na Manyan Kayayyakin Laparoscope guda 5 a China (2022-2025) ta hanyar Adadin Talla
Na'urar hangen nesa ta Hysteroscope
Adadin siyan kayan aiki masu alaƙa ya kai raka'a/saiti/rukuni 2,672, tare da jimlar darajar tallace-tallace ta RMB biliyan 1.14. Kasuwar hannun jari ta hanyar kudaden shiga ga manyan samfuran an rarraba ta kamar haka: Hangzhou Suode (26.04%), KMSMED (17.02%), Shenyang Shenda (16.70%), Karl Storz (14.21%), da Olympus (9.42%). Manyan samfuran uku sun ƙunshi kashi 59.76% na kasuwar.
Hoto na 7: Yanayin Kasuwa na Manyan Kayayyakin Hysteroscope guda 5 a China (2022-2025) ta hanyar Adadin Talla
Colposcope
Adadin siyan kayan aiki masu alaƙa ya kai raka'a/saiti/rukuni 922, tare da jimlar darajar tallace-tallace ta RMB miliyan 168. Kasuwar hannun jari ta hanyar kudaden shiga ga manyan samfuran an rarraba ta kamar haka: Edan (42.51%), ZONSUN (27.57%), TRME (16.00%), Jinyuan Medical (6.72%), da Leisegang (2.89%). Manyan samfuran uku sun ƙunshi kashi 86.08% na kasuwar.
Hoto na 8: Yanayin Kasuwa na Manyan Kayayyakin Colposcope guda 5 a China (2022-2025) ta hanyar Adadin Talla
Ureteroscope / Nephroscope
Adadin siyan kayan aiki masu alaƙa ya kai raka'a/saiti/rukuni 2,948, tare da jimlar darajar tallace-tallace ta RMB miliyan 496. Kasuwar hannun jari ta hanyar kudaden shiga ga manyan samfuran an rarraba ta kamar haka: Hawk Medical (27.11%), Richard Wolf (21.22%), Shenyang Shenda (14.37%), Woek Medical (11.57%), da Karl Storz (8.80%). Manyan samfuran uku sun ƙunshi kashi 62.70% na kasuwar.
Hoto na 9: Yanayin Kasuwa na Manyan Kayayyakin Ureteroscope/Nephroscope guda 5 a China (2022-2025) ta hanyar Adadin Talla
Discope
Adadin siyan kayan aiki masu alaƙa ya kai raka'a/saiti/rukuni 664, tare da jimlar darajar tallace-tallace ta RMB miliyan 552. Kasuwar hannun jari ta hanyar kudaden shiga ga manyan samfuran an rarraba ta kamar haka: DRAGON CROWN (19.00%), Shenyang Shenda (18.55%), unintech (17.05%), joimax (12.77%), da CANSUN (11.06%). Manyan samfuran uku sun ƙunshi kashi 54.60% na kasuwar.
Hoto na 10: Yanayin Kasuwa na Manyan Kayayyakin Discope guda 5 a China (2022-2025) ta hanyar Adadin Talla
Choledochoscope
Adadin siyan kayan aiki masu alaƙa ya kai raka'a/saiti/rukuni 665, tare da jimlar darajar tallace-tallace ta RMB miliyan 362. Kasuwar hannun jari ta hanyar kudaden shiga ga manyan samfuran an rarraba ta kamar haka: Shanghai Outai (28.22%), Micro-Tech (22.01%), Olympus (21.80%), OptoMedic (15.22%), da SMOIF (4.32%). Manyan samfuran uku sun ƙunshi kashi 72.03% na kasuwar.
Hoto na 11: Yanayin Kasuwa na Manyan Kayayyakin Choledochoscope guda 5 a China (2022-2025) ta hanyar Adadin Talla
Cystoscope
Adadin sayayya na kayan aiki masu alaƙa ya kai raka'a/saiti/rukuni 1,045, tare da jimlar darajar tallace-tallace ta RMB miliyan 184. Kasuwar hannun jari ta hanyar kudaden shiga ga manyan samfuran an rarraba ta kamar haka: Hawk Medical (46.32%), Shenyang Shenda (19.19%), Hangzhou Suode (10.51%), Olympus (9.77%), da Richard Wolf (9.19%). Manyan samfuran uku sun ƙunshi kashi 76.02% na kasuwar.
Hoto na 12: Yanayin Kasuwa na Manyan Kayayyakin Cystoscope guda 5 a China (2022-2025) ta hanyar Adadin Talla
Duodenoscope
Adadin siyan kayan aiki masu alaƙa ya kai raka'a 433/sets/rukuni, tare da jimlar darajar tallace-tallace ta RMB miliyan 350. Kasuwar hannun jari ta hanyar kudaden shiga ga manyan samfuran an rarraba ta kamar haka: Olympus (61.98%), Fujifilm (11.85%), Sonoscape (11.35%), Aohua (8.34%), da Pentax (3.86%). Manyan samfuran uku gaba ɗaya sun kai kashi 85.18% na kasuwar.
Otorhinolaryngoscope
Adadin sayayya da aka yi wa kayan aikin da suka dace ya kai raka'a 2,566/set/rukuni, tare da jimillar kuɗin shiga na tallace-tallace na biliyan 1.295. Kason kasuwa na manyan samfuran kamar haka: Olympus (28.27%), Aohua (14.62%), Shenyang Shenda (14.51%), Delong (Fanxing) (13.67%), da XION (11.20%). Manyan samfuran uku sun haɗu sun kai kashi 57.40%.
Hoto na 13: Yanayin Kasuwa na Manyan Kayayyakin Otorhinolaryngoscope guda 5 a China (2022-2025) ta hanyar Adadin Talla
3. Samfurin Samfuri
Matsayin Samfura
Olympus tana da matsayi mai rinjaye a duk sassan kasuwa. Jerin CV ɗinta sun yi fice a kasuwa, tare da samfuran kamar CV-290 da CV-1500 suna ba da kyakkyawan aikin tallace-tallace.
Samfura na Manyan Alamu
Olympus tana da matsayi mai rinjaye a duk sassan kasuwa. Jerin CV ɗinta sun yi fice a kasuwa, tare da samfuran kamar CV-290 da CV-1500 suna ba da kyakkyawan aikin tallace-tallace.
4. Sashen Siyayya
Rarraba Raka'o'in Siyayya
A shekarar 2025, asibitoci na manyan makarantu da na sakandare sun kai kashi 74.35% da 24.48% na sayayya, bi da bi.
Nau'in Sayayya
Dangane da nau'in kayan sayayya, asibitoci na gabaɗaya da asibitocin TCM sun kai kashi 74.35% da 24.48% na sayayya a shekarar 2025, bi da bi.
5. Yanki
Rarraba Yankuna
A shekarar 2025, yankin Gabas ya fi samun kaso mafi girma na yawan sayayya da kashi 43.58%, sai yankin Yamma da kashi 32.55%. Hoto na 16 ya nuna yadda ake rarraba sayayya a yankuna daban-daban. Dangane da larduna, manyan biyar sune Guangdong, Sichuan, Shandong, Zhejiang, da Jiangsu.
Manyan Alamu ta Lardi
Dangane da nau'ikan samfura daga larduna, manyan larduna biyar suna ƙarƙashin Olympus da Karl Storz.
Manyan Raka'o'in Siyayya ta Lardi
6. Takaitaccen Bayani
A shekarar 2025, an ayyana kasuwar endoscope ta kasar Sin ta hanyoyi guda uku: yawan masu amfani da ita a kasuwa, karuwar kamfanonin cikin gida, da kuma rarraba albarkatu.
Jimillar sayayya ta shekara-shekara ta kai yuan biliyan 40.82. Kasuwar tana ƙarƙashin manyan manyan kamfanoni uku na ƙasashen waje—Olympus, Karl Storz, da Fujifilm—wadanda ke da kashi 65% na kasuwa, suna riƙe da ikon mallakar manyan fannoni kamar gastroscopes da duodenoscopes. A halin yanzu, zakarun cikin gida kamar Sonoscape da Mindray sun cimma nasarori a fannoni daban-daban kamar laparoscopes da colposcopes, inda suka zarce abokan hamayya na ƙasashen waje a wasu fannoni.
Saboda zurfafa manufofin samar da kayayyakin kiwon lafiya da kuma "Aikin Gundumar Dubu," kasuwar tana hanzarta zuwa hanyoyin magance matsalolin da suka shafi lafiya, masu hankali, da kuma na gida. A nan gaba, fasahohi kamar fasahar 4K mai matuƙar inganci, hoton 3D, da kuma ganewar asali ta hanyar amfani da fasahar AI za su zama siffofi na yau da kullun. An yi hasashen cewa tsakanin 2026 da 2027, jimillar kason kasuwa na samfuran cikin gida zai wuce kashi 35%. Bugu da ƙari, buƙatar daga asibitoci na matakin gundumomi da cibiyoyin kula da lafiya na farko za ta ci gaba da ƙaruwa, wanda zai zama sabon injin ci gaba ga kasuwa.
Ana ba da shawarar cewa kamfanoni su ƙarfafa kirkire-kirkire na fasaha, su mai da hankali kan wuraren da ke fama da rashin lafiya, sannan su hanzarta haɓaka kayayyaki cikin hikima; ya kamata cibiyoyin saka hannun jari su mai da hankali kan taga damar maye gurbin gida da kuma shimfida hanyoyin samar da kayayyaki na asali; ya kamata cibiyoyin kiwon lafiya su kimanta aikin kayan aiki, tallafin sabis da cikakken farashin zagayowar rayuwa, sannan su tsara tsare-tsaren siye a kimiyyance.
A ZRHmed, ba ma yin endoscopes. Mu ne muke yin kayan aikin da ke sa su yi aiki -hemoclipsdon sarrafa zubar jini,tarkunan polypectomydon cire polyps,allurar sclerotherapydon isar da endoscopic daidai,goge gogedon tsaftacewa sosai da sauransu.
Yayin da manyan kamfanoni ke fafatawa don samun kanun labarai, muna mai da hankali kan abin da muke yi mafi kyau: isar da kayan haɗi masu inganci, masu alamar CE da kuma amincewar FDA 510 ga masu rarrabawa a duk duniya.
Domin kuwa babban tsari yana buƙatar fiye da babban tsari. Yana buƙatar kayan haɗi masu kyau.
Lokacin Saƙo: Afrilu-22-2026